RxDoctor Payments DataLook up a doctor →

Amanda Hathaway, MD

Hematology & Oncology · Athens, GANPI 1225322431

Payments from drug & device makers

$488,441in general payments, 2019–2025

Across 824 payments — averaging $592.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$178K
  • Lilly USA, LLC$114K
  • Merck$58K
  • Eli Lilly$53K
  • Genentech, Inc.$41K
  • AstraZeneca$19K
  • plus $24K from 54 others
$475in research payments, 2019–2025

Across 1 payment — averaging $475.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$475

What the payments were for

  • Consulting fees$11,4137%
  • Speaking & faculty fees$118,48775%
  • Travel & lodging$11,6327%
  • Food & beverage$13,6469%
  • Education$2600%
  • Gifts$9671%
  • Other$2,1651%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astrazeneca UK Limited4$178,309
Lilly USA, LLC192$114,163
Merck34$58,222
Eli Lilly8$53,234
Genentech, Inc.3$40,750
AstraZeneca(2 entities)60$19,076
Novartis73$9,267
Immunomedics, Inc.2$2,200
Gilead(2 entities)29$1,982
Pharmacosmos Therapeutics Inc.1$1,500
Daiichi Sankyo Inc.18$1,469
Beigene USA, Inc.5$761
Johnson & Johnson33$664
Pfizer43$619
Genentech USA, Inc.32$566
AbbVie16$390
E.r. Squibb & Sons, L.L.C.26$332
GSK17$332
Bristol Myers Squibb15$298
Amgen17$259
Bayer11$258
Puma Biotechnology, Inc.14$226
Pharmacyclics LLC, An Abbvie Company8$222
Sanofi10$215
Regeneron Healthcare Solutions, Inc.6$207
Astellas Pharma US Inc9$207
Eisai Inc.12$205
Sobi, Inc8$173
Seagen Inc.7$166
Takeda Pharmaceuticals U.S.A., Inc.7$162
Stemline Therapeutics Inc.7$158
Incyte Corporation9$147
Exelixis Inc.5$107
Rigel Pharmaceuticals, Inc.5$105
Kyowa Kirin, Inc.7$100
Pharmaessentia USA Corporation5$100
Jazz Pharmaceuticals Inc.3$91
Agios Pharmaceuticals, Inc.2$83
Ipsen Biopharmaceuticals, Inc3$77
Sumitomo Pharma America, Inc.3$61
Iovance Biotherapeutics, Inc.2$58
Genmab U.S., Inc.2$54
Dendreon Pharmaceuticals LLC2$53
Beone Medicines USA, Inc.2$48
Boehringer Ingelheim2$45
GE HealthCare2$45
Servier Pharmaceuticals LLC2$45
Taiho Oncology, Inc.2$44
Array Biopharma Inc5$42
G1 Therapeutics, Inc.2$40
Adaptive Biotechnologies Corporation2$37
Clovis Oncology, Inc.3$36
AMAG Pharmaceuticals, Inc.3$35
Spectrum Pharmaceuticals Inc.2$34
EMD Serono, Inc.2$32
Karyopharm Therapeutics Inc.1$28
Tempus AI, Inc1$26
Blueprint Medicines Corporation1$24
Sirtex Medical Inc2$23
Recordati_rare_diseases_inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$488,441 in reported general payments places this provider in the 85th percentile of 370 hematology & oncology providers in Georgia.

See all hematology & oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$1,795,498
Medicare patients
514
Services billed
78,160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide13$280,312
ZejulaNiraparib Tosylate12$213,771
Neulasta OnproPegfilgrastim20$126,088
VenclextaVenetoclax14$123,033
EliquisApixaban42$32,951
ProliaDenosumab11$18,738
XareltoRivaroxaban15$10,802
Letrozole177$2,723
Tamoxifen Citrate80$1,218
Mirtazapine38$1,119
Raloxifene Hcl36$918
Duloxetine Hcl61$914
Dexamethasone34$677
Pantoprazole Sodium62$495
Anastrozole21$450

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$332$280,31213 claims
GSKZejula$332$213,77112 claims
AbbVieVenclexta$390$123,03314 claims
PfizerEliquis$619$32,95142 claims
AmgenProlia$259$18,73811 claims
Johnson & JohnsonXarelto$664$10,80215 claims
Lilly USA, LLCOlanzapine$114,163$40718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 370 hematology & oncology providers in Georgia.

Other hematology & oncology in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →